Argenx SE 2024 IR
The report highlights argenx's significant progress in 2024, achieving global product net sales of $2.2 billion, driven by the commercial expansion of VYVGART and VYVGART SC. The company received FDA approval for VYVGART HYTRULO for chronic inflammatory demyelinating polyneuropathy (CIDP) and Japanese approval for primary immune thrombocytopenia (ITP). Additionally, argenx advanced its clinical pipeline, initiating Phase 3 trials for empasiprubarb in multifocal motor neuropathy (MMN) and proof-of-concept studies for ARGX-119. The company also prepared its first sustainability statement in alignment with the European Union's Corporate Sustainability Reporting Directive (CSRD).
Company: Argenx SE
Sector: Health Care
Country: Netherlands
Year: 2024
Type: IR
Pages: 384
Argenx SE
Annual Report
The report highlights argenx's significant progress in 2024, achieving global product net sales of $2.2 billion, driven by the commercial expansion of VYVGART and VYVGART SC. The company received FDA approval for VYVGART HYTRULO for chronic inflammatory demyelinating polyneuropathy (CIDP) and Japanese approval for primary immune thrombocytopenia (ITP). Additionally, argenx advanced its clinical pipeline, initiating Phase 3 trials for empasiprubarb in multifocal motor neuropathy (MMN) and proof-of-concept studies for ARGX-119. The company also prepared its first sustainability statement in alignment with the European Union's Corporate Sustainability Reporting Directive (CSRD).
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees